RTSHLTs (refer to the respective measure chapters in the main report), and the activities of similar projects and programs funded by jurisdictions. (Refer the Policy Map for details of these projects). There was strong evidence of networking and partnerships with other projects and programs in the regions, including organisations that contributed funding and other resources (refer to the A3 measure chapter in the main report). There is evidence that the measure strengthened the capacity of sites to develop local initiatives. Subsidising PBS Medicine Co-payments (B1) measure Table 348: B1 Early outcomes – description, inclusion or exclusion in analyses and Evaluation Framework data expectations for June 2013. B1 early Inclusion in analyses Evaluation framework data expectations on outcomes specific indicators B1_1 Included in evidence map Number of patients dispensed at least one Closing the Gap (CtG) scriptb; Participating Included in analysis of other patients have influencing factors Proportion of PIP Indigenous Health Incentive reduced (B3) registered participants who access PBS Included in evidence map financial Included in analysis of other barriers to Proportion of CtG scripts dispensed by influencing factors purchasing Anatomical Therapeutic Chemical (ATC) pharmaceuticals classesb for chronic Number of patients dispensed medicines disease through S100 RAAHS* management Access barriers identified by prescribers and dispensersb; Barriers identified by community membersb; Responses to access barriers identified (local, state and national level)b; Volume of CtG concession scripts and scriptsb; and Perceived impact of co-payment relief on reduced financial barriersb B1_2 Included in evidence map Number of CtG scripts dispensedb; Participating Activities external to the Numbers and locations of people accessing patients ICDP are likely to influence medicines through the program – (i.e., number increase their this outcome of patients receiving at least one CtG script by utilisation of remoteness area and jurisdiction)b; PBS medicines Number of CtG scripts dispensed per patientb for the PBS utilisation of participants before and after management of the measure compared to S100 and compared chronic disease, to all Australiansb; in accordance Proportion of CtG scripts dispensed by ATC with Care Plans classesc PBS utilisation of Aboriginal and Torres Strait
RTSHLTs (refer to the respective measure chapters in the main report), and the activities of similar projects and programs funded by jurisdictions. (Refer the Policy Map for details of these projects). There was strong evidence of networking and partnerships with other projects and programs in the regions, including organisations that contributed funding and other resources (refer to the A3 measure chapter in the main report). There is evidence that the measure strengthened the capacity of sites to develop local initiatives. Subsidising PBS Medicine Co-payments (B1) measure Table 348: B1 Early outcomes – description, inclusion or exclusion in analyses and Evaluation Framework data expectations for June 2013. B1 early outcomes Inclusion in analyses Evaluation framework data expectations on specific indicators B1_1 Participating patients have reduced financial barriers to purchasing pharmaceuticals for chronic disease management Included in evidence map Included in analysis of other influencing factors Included in evidence map Included in analysis of other influencing factors Number of patients dispensed at least one Closing the Gap (CtG) scriptb; Proportion of PIP Indigenous Health Incentive (B3) registered participants who access PBS Proportion of CtG scripts dispensed by Anatomical Therapeutic Chemical (ATC) classesb Number of patients dispensed medicines through S100 RAAHS* Access barriers identified by prescribers and dispensersb; Barriers identified by community membersb; Responses to access barriers identified (local, state and national level)b; Volume of CtG concession scripts and scriptsb; and Perceived impact of co-payment relief on reduced financial barriersb B1_2 Participating patients increase their utilisation of PBS medicines for the management of chronic disease, in accordance with Care Plans Included in evidence map Activities external to the ICDP are likely to influence this outcome Number of CtG scripts dispensedb; Numbers and locations of people accessing medicines through the program – (i.e., number of patients receiving at least one CtG script by remoteness area and jurisdiction)b; Number of CtG scripts dispensed per patientb PBS utilisation of participants before and after the measure compared to S100 and compared to all Australiansb; Proportion of CtG scripts dispensed by ATC classesc PBS utilisation of Aboriginal and Torres Strait
ICDP_appendices_vol4.docx